Lipella pharmaceuticals expands its advisory board to include oncology expertise

The new oncology committee will include: jason hafron, md, dds, phd, mph; and pradeep tyagi, phd, mba pittsburgh, pa, april 17, 2024 – lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella” or the “company”), a clinical-stage biotechnology company, today announced the expansion of its scientific advisory board to include oncology expertise.
LIPO Ratings Summary
LIPO Quant Ranking